Trials / Completed
CompletedNCT00630058
A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C
A Phase I, Open-Label, Two-Arm Study of MP-424 in Combination With Peginterferon Alfa 2b and Ribavirin in Patients With Genotype 1b Hepatitis C
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa 2b (PEG-IFN-a-2b) and Ribavirin (RBV) to patients with chronic hepatitis C.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-424(H), PEG-IFN-a-2b, RBV | MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks |
| DRUG | MP-424 (L), PEG-IFN-a-2b, RBV | MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2008-03-06
- Last updated
- 2026-01-06
- Results posted
- 2013-01-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00630058. Inclusion in this directory is not an endorsement.